Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dichlorphenamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 15/20 | 1.00 |
| ▸ | CA2 known ✓ | P00918 | 15/20 | 1.00 |
| ▸ | CA4 known ✓ | P22748 | 7/20 | 1.00 |
| ▸ | CA12 known ✓ | O43570 | 6/20 | 1.00 |
| ▸ | CA9 | Q16790 | 12/20 | 1.00 |
| ▸ | CA7 | P43166 | 7/20 | 1.00 |
| ▸ | CA6 | P23280 | 6/20 | 1.00 |
| ▸ | CA5A | P35218 | 6/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 5/20 | 0.45 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dichlorphenamide SCHEMBL29355725 | 1.00 | CA1 (1.00) | CA1CA2CA9CA4CA7 | |
| Dichlorphenamide SCHEMBL4312398 | 0.98 | CA1 (0.96) | CA1CA2CA9CA4CA7 | |
| Dichlorphenamide SCHEMBL7040074 | 0.98 | CA1 (0.96) | CA1CA2CA9CA4CA7 | |
| Dichlorphenamide SCHEMBL7034594 | 0.98 | CA1 (0.96) | CA1CA2CA9CA4CA7 | |
| SCHEMBL7993257 | 0.86 | CA2 (0.75) | CA1CA2CA9CA4CA7 | |
| Dichlorphenamide SCHEMBL298941 | 0.83 | CA2 (0.70) | CA1CA2CA9CA4CA7 | |
| SCHEMBL9518035 | 0.83 | APEX1 (1.00) | CA1CA2CA9CA4CA7 | |
| SCHEMBL17471595 | 0.81 | CA1 (0.68) | CA1CA2CA9CA4CA7 | |
| SCHEMBL11929253 | 0.81 | CA1 (0.68) | CA1CA2CA9CA4CA7 | |
| SCHEMBL9699791 | 0.81 | CA1 (0.68) | CA1CA2CA9CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9520 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630599-B2 | CA2 compositions and methods for tunable regulation | OBSIDIAN THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | claimed |
| US-20260083692-A1 | METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE | STRONGBRIDGE DUBLIN LIMITED (US) | 2026-03-26 | — | — | US | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250241933-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) | 2025-07-31 | — | — | US | claimed |
| EP-0126684-B1 | DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS | MERCK & CO. INC. (US) | 1991-08-28 | — | — | EP | claimed |
| EP-0419311-A2 | Prodrugs of carbonic anhydrase inhibitors | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1991-03-27 | — | — | EP | claimed |
| WO-1990015600-A2 | TREATMENT OF CHRONIC INFLAMMATORY JOINT DISEASE WITH ARYLSULFONAMIDES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-12-27 | — | — | WO | claimed |
| EP-0036351-B1 | OPHTHALMIC COMPOSITIONS OF CARBONIC ANHYDRASE INHIBITORS FOR TOPICAL APPLICATION IN THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1985-01-02 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| EP-0014642-B1 | OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF CARBONIC ANHYDRASE INHIBITORS AND S-(-)-1-(TERT-BUTYLAMINO)-3-(4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)-OXY-2-PROPANOL FOR TOPICAL APPLICATION IN THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1984-03-21 | — | — | EP | claimed |
| EP-0036351-A2 | Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0033042-A1 | Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors | MERCK & CO. INC. (US) | 1981-08-05 | — | — | EP | claimed |
| EP-0014642-A2 | Ophthalmic compositions comprising combinations of carbonic anhydrase inhibitors and S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol for topical application in the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1980-08-20 | — | — | EP | claimed |